"What is the rational of waiting an extra 2 months to announce the %RRR of Bet on Mace?"

As Tada indicated, it is par for the course for cardio outcomes trials to announce at top-line whether or not the primary endpoint was met but to reserve the %RRR for full data presentation.

Plus, as Tada suggested a positive top-line announcement will grab a ton of attention for Resverlogix, allowing folks to figure out the who, what, when, where, why and how about Resverlogix, epigenetics, BET inhibition, apabetalone  and BETonMACE (for those who aren't already aware and in the know). A great set up in advance of full data (at AHA?) and also a great set up for that potential US listing. Resverlogix seems off the radar still, so a positive top-line announcement, even without %RRR, is the perfect way to open eyes and get some coverage and attention.

BearDownAZ